Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Smith SM et al. – Despite the small benefit in EFS in patients with PR randomized to IFN–alpha2 maintenance, the authors conclude that the addition of low dose IFN–alpha2 did not significantly improve the response rate, duration of response, event–free, or OS obtained with single–agent daily oral CPA in patients with previously untreated FL.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address